<DOC>
	<DOCNO>NCT01127893</DOCNO>
	<brief_summary>An evaluation long term safety tanezumab administer subcutaneous injection every 8 week 64 week</brief_summary>
	<brief_title>Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection To Patients With Osteoarthritis</brief_title>
	<detailed_description>This study terminate 29 September 2010 follow US FDA clinical hold tanezumab osteoarthritis clinical study halt dose enrollment patient 23 June 2010 potential safety issue .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>Must participate specific Phase 3 parent study Failed screen parent study , pregnant woman , lactate mother</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Musculoskeletal Diseases</keyword>
	<keyword>Joint Diseases</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Rheumatic Diseases</keyword>
</DOC>